Abstract
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, the launch of Project Optimus in 2022 by the US Food and Drug Administration (FDA) represents a much‐needed shift in the way that drug trials in cancer are conducted. In addition, the FDA approves the first immunotherapy drug for nasopharyngeal carcinoma, and Cancer Statistics 2024 reports on cancer facts and trends by the American Cancer Society.